Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Q4 2022 Earnings Presentation
25 slides from Vitrolife Ab's earnings presentation, Feb 2, 2023
Slide 1: Vitrolife Group - Excellence in Reproductive Health
Slide 2: Investor Presentation
Investor Presentation Vitrolife AB (publ) 2023-02-02
Slide 3: 10-15% of all couples in fertile age suffer from fertility problems
10 – 15% of all couples in fertile age suffer from fertility problems
Slide 4: Vitrolife Group - Excellence in reproductive health
Vitrolife Group - Excellence in reproductive health Global presence in 110 markets Employees Sales per year Vitrolife AB (publ) listed on ~1,100 ~SEK 3 BN NASDAQ Best-in-class IVF Leadership in Stockholm Large Cap medical devices reproductive portfolio genetic testing services Founded 1994 Founded 2
Slide 5: Strong underlying growth with solid drivers in the IVF market
Strong underlaying growth with solid drivers in the IVF market • Delay in motherhood Demographic & social trends • Social acceptances and awareness of IVF • Lifestyle and social changes Top 5 markets worldwide North America • Improvement in IVF lab procedures (i.e. incubation system) Technical impro
Slide 6: Outcomes
Success rates “STEP BY STEP” Outcomes of ART Cycles Using Fresh Nondonor Eggs or IVF clinics way of Embryos working is essential 160,000 for a successful treatment 140,000 120,000 Intended retrievals 100,000 Retrievals Outcomes 138,328 Transfers 125,009 80,000 107,795 60,000 40,000 Live-birth delive
Slide 7: Innovative embryo evaluation and leading diagnostic tool to find window of implantation
Innovative embryo evaluation and leading diagnostic tool to find window of implantation Two of the strongest names within reproductive health into one platform to achieve successful treatment outcomes Two methods for embryo evaluation Combination improves successful treatment outcomes The right embr
Slide 8: Supporting clinics in every step of the reproductive health journey
Supporting clinics in every step of the reproductive health journey 8
Slide 9: Operating structure Vitrolife Group
Operating structure Vitrolife Group Executive Management and Group Functions Finance, Legal, IT, Strategy and HR & Sustainability Global Sales & Marketing Commercial excellence, Customer Services, Vitrolife Academy Media, cryo products, disposable devices and Incubation, time-lapse evaluation and la
Slide 10: Our financial objectives
Our financial objectives Profitable growth SALES GROWTH In local currencies, average 3 years +20% EBITDA MARGIN >30% NET DEBT/EBITDA <3 10
Slide 11: Fourth Quarter and Full Year report / 2022
Fourth Quarter and Full Year report / 2022 2023-02-02 Vitrolife AB (publ) Thomas Axelsson, CEO Patrik Tolf, CFO
Slide 12: Strong profitable growth
Strong profitable growth Fourth quarter Sales Organic growth* Adjusted gross margin 855 MSEK +11% 56.5% +66% in SEK In local currencies (56.9 % Pro forma) EBITDA EBITDA per share Operating cash flow 273 MSEK 2.02 SEK 166 MSEK Margin 31.9% (27.8% Pro forma) +196% (0 MSEK) Full year 2022 Sales Organic
Slide 13: Sales and growth per market region
Sales and growth per market region Total Q4 growth rate (local currencies) 81% 31% 32% 56% 48% Organic growth (local currencies) 8% 2% 21% 29% 11% Growth pro forma* (local currencies) 1% 6% 15% 24% 7% Sales (MSEK) 303 316 138 98 855 Share of Vitrolife 35% 37% 16% 12% Group’s sales 13 * Pro forma: Ex
Slide 14: Consumables business area
Consumables business area 23% 348 349 334 10% In local currencies 307 280 284 284 243 -1% 1% Americas EMEA 32% 27% Asia Japan Pacific Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 2022 Net sales, MSEK 14
Slide 15: Technologies business area
Technologies business area 36% 156 27% In local currencies 141 140 136 122 115 116 102 25% 25% Americas EMEA 16% 46% Asia Japan Pacific Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 2022 Net sales, MSEK 15
Slide 16: Genetic Services business area (pro forma)
Genetic Services business area (pro forma)* 14% 347 349 337 -2% in local currencies 307 293 283 279 246 -1% 2% Americas EMEA -32% 0% Asia Japan Pacific Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 2022 Net sales, MSEK 16 *Genetic Services excluding business related to Covid-19 tests
Slide 17: Q4 financial highlights
Q4 financial highlights Net sales of SEK 855 million (514), + 66% in SEK MSEK 855 • Positive impact from currencies of SEK 94 million (18%) • Organic growth in local currencies 723 • 11% total sales • 7% pro forma excluding Covid-19 tests • 9% pro forma excluding Covid-19 tests and divested China bu
Slide 18: Operating expenses
Operating expenses MSEK +5% 295 281 Increased expenses • Sales and Marketing activities • Group related projects • Staff and personal cost • Negative exchange rate impact 20 MSEK Decreased expenses • Exploratory research • Group related projects 21Q4 22Q4 Pro forma 21Q4 18
Slide 19: Key financials
Key financials 2022 2021 2021 Q4 Delta Pro forma Full year 2022 Full year 2021 Q4 Q4 Pro forma Sales, MSEK 855 514 723 +132 3,234 1,681 Gross Margin, % 54% 58% 54% - 55% 62% Adj. Gross Margin, %* 57% 60% 57% - 57% 63% Adjusted EBITDA, MSEK** 273 164 201 +72 1,050 645 Adjusted EBITDA, %** 32% 32% 28%
Slide 20: Management comments
Management comments • Vitrolife Group - significant changes done • Time-lapse is becoming standard of care in several markets • Strong profitable growth • A better-balanced company between regions and between business areas 20
Slide 21: Bronwyn Brophy is appointed as new CEO
• Bronwyn Brophy is appointed as new CEO. She will join the company at the latest of 1 August 2023. • The Chairman of the Board, Jón Sigurdsson will assume the position as interim CEO from 1 April 2023. • Board member, Henrik Blomquist, will be the Chairman of the board from 1 April 2023 until the a
Slide 22: Our vision with a purpose: to fulfil the dream of having a healthy baby
Our vision with a purpose: to fulfil the dream of having a healthy baby 22
Slide 23: Contact
Contact: Thomas Axelsson, CEO, taxelsson@vitrolife.com, +46 31 721 80 01 Patrik Tolf, CFO, ptolf@vitrolife.com, +46 31 766 90 21
Slide 24: Disclaimer
DISCLAIMER This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, ther
Slide 25: Slide 25